The Lynx Group
Cholangiocarcinoma Summit
2022 Cholangiocarcinoma Summit

October 13-15, 2022
Gaylord Rockies Convention Center, Aurora CO


4th Annual Cholangiocarcinoma Summit Overview

The 2022 Cholangiocarcinoma Summit will offer an exciting mix of advances in basic and translational science as well as in-depth discussion of emerging clinical data and real-world practice patterns. The program will include practice-changing research, dynamic and diverse speakers, and a global perspective on the management of cholangiocarcinoma and other biliary tract cancers. The goal of the program is to provide a highly interactive forum to expand the knowledge of healthcare professionals and explore the latest information on cholangiocarcinoma and biliary tract cancer.

There will also be ample opportunities for networking to permit formal and informal connections for early career oncologists, mid-professionals, world-renowned experts, and industry leaders in a variety of engaging and innovative forums, to allow for collaboration among the global cholangiocarcinoma community.

“Save the Date” for our 2022 Summit taking place October 13-15, 2022, at the Gaylord Rockies Convention Center, Aurora, CO. Registration details coming soon!

CCA ONE Award

The CCA Summit organizers are pleased to announce the continuation of the Cholangiocarcinoma Oncology Nurse of Excellence (ONE) Award to our 4th Annual Cholangiocarcinoma Summit!

The CCA ONE Award recognizes an oncology nurse for their outstanding contributions to nursing practice, patient care, or education in the cholangiocarcinoma field in 2022. Nomination details coming soon!

Thank You to our 2021 Summit Supporters & Partners

  • Helsinn
  • QED Therapeutics
  • Incyte
  • AstraZeneca
  • Elevation Oncology
  • Ethicon
  • Foundation Medicine
  • Kinnate Biopharma
  • Merck
  • Taiho Oncology
  • Zymeworks
  • Cholangiocarcinoma Foundation

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: